Sucampo

Here’s why Sucampo paid $200M for its PhIII Niemann-Pick drug
Here’s why Sucampo paid $200M for its PhIII Niemann-Pick drug
Endpoints
Sucampo
Niemann-Pick disease
cyclodextrin
Flag link:
Sucampo bags rare disease player Vtesse in $200M buyout agreement
Sucampo bags rare disease player Vtesse in $200M buyout agreement
Endpoints
Sucampo
Vtesse
M&A
VTS-270
Flag link:
Sucampo tops 4Q revenue forecasts
Sucampo tops 4Q revenue forecasts
Yahoo/AP
Sucampo
earnings
Flag link:
Sucampo Q4 Beats Estimates, Affirms Guidance, Driving Up Stock
Sucampo Q4 Beats Estimates, Affirms Guidance, Driving Up Stock
Investors.com
Sucampo
earnings
Flag link:
10 Best Nasdaq Biotech Stocks in the Third Quarter
10 Best Nasdaq Biotech Stocks in the Third Quarter
TheStreet.com
Incyte
Myriad
Cara Therapeutics
Sucampo
ZS Pharma
Concert Pharmaceuticals
The Medicines Company
Lexicon Pharmaceuticals
Exelixis
Anacor
Flag link:
Why does Sucampo want to acquire its founders' Japanese company? Transformation.
Why does Sucampo want to acquire its founders' Japanese company? Transformation.
Bizjournals.com
Sucampo
Japan
M&A
Flag link:
Sucampo Pharma to Make Tender Offer For Japan's R-Tech Ueno
Sucampo Pharma to Make Tender Offer For Japan's R-Tech Ueno
Bloomberg
Sucampo
M&A
Japan
R-Tech Ueno
Flag link:
19 Lesser-Known Biotech Stocks With Robust Drug Pipelines
19 Lesser-Known Biotech Stocks With Robust Drug Pipelines
Yahoo/Benzinga
biotech
Threshold Pharmaceuticals
Acceleron
Spectrum Pharmaceuticals
Ultragenyx
Argos Therapeutics
OncoMed
Peregrine Pharmaceuticals
Incyte
Calithera
Array Biopharma
Theravance
Puma Biotechnology
CTI BioPharma
Orexigen
Enanta Pharmaceuticals
Sucampo
Exelixis
Cubist Pharmaceuticals
United Therapeutics
Flag link:
Sucampo posts profit of $1.5 million in third quarter
Sucampo posts profit of $1.5 million in third quarter
Yahoo/AP
Sucampo
earnings
Flag link:
Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)
Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)
Yahoo
Takeda
Sucampo
Amitiza
Flag link:
Previous Data Signals Positive Phase IIb Results Likely To Come For Synergy Pharmaceuticals
Previous Data Signals Positive Phase IIb Results Likely To Come For Synergy Pharmaceuticals
Seeking Alpha
Synergy Pharmaceuticals
IBS-C
Ironwood Pharmaceuticals
Linzess
Sucampo
plecanatide
Flag link:
Sucampo initiates global Phase 3 clinical program of lubiprostone
Sucampo initiates global Phase 3 clinical program of lubiprostone
The Fly on the Wall
Sucampo
Lubiprostone
pediatric functional constipation
Flag link:
Sucampo CEO search an unexpected positive, says Cantor
Sucampo CEO search an unexpected positive, says Cantor
Yahoo/Fly on the Wall
Sucampo
Flag link:
Sucampo Receives $10 Million Milestone Payment from Takeda on First Sale of AMITIZA® (lubiprostone) for OIC in the US
Sucampo Receives $10 Million Milestone Payment from Takeda on First Sale of AMITIZA® (lubiprostone) for OIC in the US
Yahoo
Sucampo
Takeda
Amitiza
opioid-induced constipation
Flag link:
Sucampo to be Added to the NASDAQ Biotechnology Index
Sucampo to be Added to the NASDAQ Biotechnology Index
Yahoo
NASDAQ
Sucampo
Flag link:
Sucampo Wins Approval for Expanded Use of Amitiza in U.S.
Sucampo Wins Approval for Expanded Use of Amitiza in U.S.
Bloomberg
Sucampo
Amitiza
opioid-induced constipation
Flag link:
Strength In Sucampo Heading Into FDA Decision And Analyst Activity
Strength In Sucampo Heading Into FDA Decision And Analyst Activity
Seeking Alpha
Sucampo
FDA
Rescula
Amitiza
opioid-induced constipation
Flag link:
Most Profitable Second Quarter Biotech Stocks
Most Profitable Second Quarter Biotech Stocks
TheStreet.com
Arena Pharmaceuticals
Zogenix
Delcath
Aveo Pharmaceutical
Vivus
Titan Pharmaceuticals
Bristol-Myers Squibb
Merck
Gilead
AbbVie
Amarin
Achillion
Sangamo BioSciences
Raptor Pharmaceuticals
Vertex Pharmaceuticals
NewLink Genetics
AstraZeneca
Rigel
Depomed
Biogen Idec
Sucampo
Dendreon
Valeant Pharmaceuticals
GSK
Aegerion
Flag link:
Sucampo Should See Revenue From 3 Continents By Year-End
Sucampo Should See Revenue From 3 Continents By Year-End
Seeking Alpha
Sucampo
Rescula
Amitiza
Flag link:
US FDA grants approval for Sucampo's sNDA for Rescula
US FDA grants approval for Sucampo's sNDA for Rescula
Pharmabiz
Rescula
ocular hypertension
glaucoma
open angle glaucoma
Sucampo
Flag link: